Xopenex (levalbuterol) is a brand-name inhaled medication prescribed to treat and help prevent difficulty breathing associated with bronchospasm. Xopenex comes in two forms: a solution for use with a ...

DUBLIN--(BUSINESS WIRE)--The "Xopenex - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Xopenex Drug Insight, 2019 highlights the drug marketed details and the Global ...

COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic ...

Development of levalbuterol was based on the following proposed advantages over racemic albuterol [3]: fewer episodes of transient tachycardia, better tolerability, and similar or greater efficacy. An ...

Levalbuterol (as tartrate) (single-isomer albuterol) 45mcg/inh; metered dose inhaler; CFC-free. Do not exceed recommended dose. Monitor for increased need; if inadequate control, reevaluate and ...

Teva Launches Generic Xopenex Concentrate Teva announced the launch of Levalbuterol Inhalation Solution, the generic version of Xopenex Inhalation Solution Concentrate. Teva announced the launch of ...

Watson Pharmaceuticals has launched an authorized generic version of Xopenex (levalbuterol HCl) Inhalation Solution. This is part of an agreement Watson has with Sunovion Pharmaceuticals, who ...

XOPENEX Inhalation Solution is available for use in a nebulizer at 0.31 mg and 0.63 mg dosage strengths for treatment of children 6 to 11 years old, and in 0.63 mg and 1.25 mg dosage strengths for ...

Xopenex is approved for patients aged 6 years and above for the treatment of bronchospasm caused by asthma and chronic obstructive pulmonary disease. We note that Dr. Reddy's is a late entrant in the ...

March 17, 2005 — The U.S. Food and Drug Administration (FDA) has approved a new indication for temozolomide, allowing its use in the first-line treatment of glioblastoma multiforme; orphan drug status ...

Mylan Inc., a global pharmaceutical compan, has announced that Mylan Specialty L.P. has entered into a settlement agreement with Sunovion Pharmaceuticals Inc. to resolve the patent litigation in ...

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals ...